Shenzhen Neptunus Interlong Bio-technique Past Earnings Performance
Past criteria checks 0/6
Shenzhen Neptunus Interlong Bio-technique's earnings have been declining at an average annual rate of -2.3%, while the Pharmaceuticals industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 1.4% per year. Shenzhen Neptunus Interlong Bio-technique's return on equity is 1.4%, and it has net margins of 2.3%.
Key information
-2.3%
Earnings growth rate
-2.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 5.6% |
| Revenue growth rate | 1.4% |
| Return on equity | 1.4% |
| Net Margin | 2.3% |
| Next Earnings Update | 27 May 2024 |
Recent past performance updates
Recent updates
We Think You Can Look Beyond Shenzhen Neptunus Interlong Bio-technique's (HKG:8329) Lackluster Earnings
Apr 19
These 4 Measures Indicate That Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Is Using Debt Safely
Oct 03Is Shenzhen Neptunus Interlong Bio-technique (HKG:8329) A Risky Investment?
Mar 29We Think Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Can Stay On Top Of Its Debt
Sep 28A Look At The Intrinsic Value Of Shenzhen Neptunus Interlong Bio-technique Company Limited (HKG:8329)
Aug 18Does Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Have A Healthy Balance Sheet?
Jun 06Is Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Using Too Much Debt?
Dec 15Shenzhen Neptunus Interlong Bio-technique's(HKG:8329) Share Price Is Down 49% Over The Past Five Years.
Dec 29Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Seems To Use Debt Rather Sparingly
Nov 24Revenue & Expenses Breakdown
How Shenzhen Neptunus Interlong Bio-technique makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,065 | 24 | 346 | 0 |
| 30 Sep 23 | 1,120 | 64 | 379 | 0 |
| 30 Jun 23 | 1,103 | 64 | 380 | 0 |
| 31 Mar 23 | 1,071 | 60 | 375 | 0 |
| 31 Dec 22 | 987 | 54 | 341 | 0 |
| 30 Sep 22 | 931 | 47 | 324 | 0 |
| 30 Jun 22 | 886 | 37 | 315 | 0 |
| 31 Mar 22 | 835 | 31 | 303 | 0 |
| 31 Dec 21 | 839 | 36 | 321 | 0 |
| 30 Sep 21 | 868 | 33 | 379 | 0 |
| 30 Jun 21 | 963 | 38 | 442 | 0 |
| 31 Mar 21 | 1,056 | 43 | 506 | 0 |
| 31 Dec 20 | 1,031 | 37 | 485 | 0 |
| 30 Sep 20 | 1,077 | 52 | 472 | 0 |
| 30 Jun 20 | 1,065 | 59 | 473 | 0 |
| 31 Mar 20 | 1,059 | 57 | 492 | 0 |
| 31 Dec 19 | 1,081 | 60 | 522 | 0 |
| 30 Sep 19 | 1,006 | 56 | 491 | 0 |
| 30 Jun 19 | 937 | 52 | 456 | 0 |
| 31 Mar 19 | 879 | 47 | 417 | 0 |
| 31 Dec 18 | 867 | 48 | 405 | 0 |
| 30 Sep 18 | 862 | 43 | 409 | 0 |
| 30 Jun 18 | 848 | 43 | 381 | 0 |
| 31 Mar 18 | 835 | 51 | 352 | 0 |
| 31 Dec 17 | 790 | 50 | 314 | 0 |
| 30 Sep 17 | 803 | 64 | 300 | 0 |
| 30 Jun 17 | 772 | 64 | 285 | 0 |
| 31 Mar 17 | 777 | 65 | 282 | 0 |
| 31 Dec 16 | 759 | 63 | 276 | 0 |
| 30 Sep 16 | 738 | 37 | 282 | 0 |
| 30 Jun 16 | 726 | 29 | 278 | 0 |
| 31 Mar 16 | 713 | 20 | 270 | 0 |
| 31 Dec 15 | 721 | 21 | 258 | 0 |
| 30 Sep 15 | 664 | 19 | 219 | 0 |
| 30 Jun 15 | 662 | 23 | 196 | 0 |
| 31 Mar 15 | 650 | 31 | 173 | 0 |
| 31 Dec 14 | 648 | 33 | 170 | 0 |
| 30 Sep 14 | 633 | 30 | 165 | 0 |
| 30 Jun 14 | 630 | 27 | 167 | 0 |
| 31 Mar 14 | 603 | 37 | 156 | 0 |
| 31 Dec 13 | 612 | 36 | 161 | 0 |
| 30 Sep 13 | 582 | 34 | 150 | 0 |
| 30 Jun 13 | 555 | 32 | 139 | 0 |
Quality Earnings: 8329 has a large one-off loss of CN¥17.9M impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: 8329's current net profit margins (2.3%) are lower than last year (5.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 8329's earnings have declined by 2.3% per year over the past 5 years.
Accelerating Growth: 8329's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 8329 had negative earnings growth (-55.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (1.3%).
Return on Equity
High ROE: 8329's Return on Equity (1.4%) is considered low.